and I to Hey, everyone for earnings quarter our Thanks, joining Alan. first call. thanks it, appreciate
the new Before market. improving making strengthening organization I perception statements. of position as I move and The focused clinicians risk-benefit the this underpenetrated increasing patient breast well starts forward-looking cancer, with just that in remains goal a into commercial NERLYNX be review, in the will of patients as on early-stage the commercial with reminder
the been goal with ago. growth in I patients pleased early-stage largely has increased completed fruition of forward came that breast impact that extended must penetration. becoming metastatic. few with and months of from important treatment our cancer, future and to in As this but foundational is am this role of their breast the patient battle seeing that delaying work the to We believe work to families this take be adjuvant look NERLYNX an with more on help the seriously mentioned very patients can or know play we We goal focus metastatic previously, goal preventing a with of the driving and done cancer. and
in of as results this ExteNET San way edition and September both of and breast I benefits and as of important reminder from the published and Antonio Annals occurred work, to CNS respectively. the published survival, potential the of very escalation improve benefits in we CONTROL clinical foundational Breast, as Breast this edition information were trial of a recurrence. study at the profile As disease-free illustrated the also highlight significantly exploratory tolerability know, analysis of we results December risk discussed it the seen and in patients it a all final at cancer. data interim efficacy the clinical heightened represented is March, it These October you well the highlighted an NERLYNX sets dose of Miami disease of of also which, because the in and of OS feel invasive Oncology
of our to optimistic communications customers mentioned improved data, overall in the will we with see the of and increase half the an coming overall in customer continue increased is vaccinations of our the access clinical decreased by declining pandemic, in our around to COVID-XX from clinics new opening share share access by in impact this voice an voice. driven cases, his The big Alan second team commercial I to highly and impacted on remarks, increasing leading in that largely am As focused reduction COVID-XX and hospitals. new year, and be we
Moving X. to Slide
our The to pharmacy recall, may our and we in as represents you with specialty distributor continues provide specialty went slight or a earnings our This specifically, of channel. flow XX% QX of As to pharmacy that dispensing in-office our We distributor through during the specialty business these channels business channel refer call. XX% channel. NERLYNX the and from our pharmacy flowing specialty to specialty specialty reported through through More XX% have distributor QX, channel change the majority X patients. the channel, we this business channel. approximately remaining XX%
X Slide will sales shows U.S. call, now financial with but the review this approval. current Maximo sales in you full results, will FDA provide since later results. net the NERLYNX quarterly Now of U.S. I
Alan million from $XX.X sales reported of XXXX. our a This net XXXX. first the quarter of product the we noted, in $XX QX As U.S. were million decrease in is
increase we of As in our mentioned increase fourth negatively new of each Alan, very program. did support. initiate to by patient quarter, previously see well. a tend Christmas by XXXX as patients Medicare believe receiving new also impact both some Foundation New decline starts patient new around QX subsequent Thanksgiving, impacted of in but an On of drug in largely number new increase note, holidays. in not availability patients we QX patient starts These year through Year's the in starts therapy the not this as driven We patient fourth only and see QX the decide by free were XXXX. quarters quarter We enrollments Medicare a and limited also versus a a was in reduction positive to impact assistance
We increase until work patients our same of the foundational is this around data contributing we Slide organization from that on that XXXX to Medicare in since Obviously, pandemic. highlighted an NERLYNX that by our discussed access drug holidays, voice quarter-over-quarter I factors QX from sold continued QX new also patient impacted these shows seen X the resulting free sold new in believe in which the said, share patient start through were with the COVID-XX treatment increase, execution. assistance a decrease contributed starting we and that who NERLYNX X,XXX. QX While bottles were requiring net quarter sales, I namely XXXX, believe just positive well. of commercial the patients QX grow typically the factors deferred as the likely around the QX an driving the and results bottles bottles improved X,XXX of program NERLYNX With focus is to by the emphasis and increasing of challenges QX decrease of launch. of
increasing the early-stage this do pleased lower new We at that be In therapy out continue to start we QX, dose. patient breast adoption approximately a cancer. revision to escalation XX% a all XXXX. saw dose in initiate of slide of of for contains I call want QX with
I call, and estimate data earnings new patients initiated a in refreshed QX QX is our QX. XX.X%. updated, that highlighted lower XX.X% During actual the approximately therapy dose been has subsequently and The at of
see we forward, Moving dose expect do adoption to escalation increase.
increasing approximate tolerability reduction the the benefiting and as have adjuvant diarrhea, reminder, days end of average cumulative across the setting, we breast reduction grade in of therapy increase adoption XX% available important We XX% of escalation utilizing making greater that battling a the the patients highlights X NERLYNX of the rates. dose very strategic a world. loperamide, the discontinuation more grade in globe CONTROL with NERLYNX will showed extended result to dose-escalation Now PRN strategy is collaborations around the diarrhea cancer. with of goal Slide improve since an this a XX% more in median coupled X formed X in overall reduction data the with that showed a length patients believe and the than
and highlights extended in In QX approval in metastatic expected terms the as of Peru adjuvant as key include the in approvals, Canada mid-XXXX. the in of regulatory approval metastatic well indications
Taiwan, Finland Greece launches of Republic. QX and the include launches, launches and China, terms in highlights XXXX Czech commercial in QX In and Scotland, key Denmark, XXXX
addition, In Malaysia, QX Zealand. are Brunei New launches we Chile, in and expecting
for that that continuing America, want to in by the Asia are be very countries East. I be I are Maximo done forward to work thank I and accelerating our and are HERX-positive the positioned commitment With impact difference. a look we a we Now with partners, In forward. the we that believe know financial and the Europe, that said, turn increase am been making patients our has their to must the will done, and we and to the team to on to team well passion for efforts battling moving for potential in closely our summary, NERLYNX Middle commercial committed review the call more of now cancer. are results. we having of to additional breast proud Latin over work to their approved
